Principal Financial Group
ACET icon

Principal Financial Group’s Adicet Bio ACET Stock Holding History

Principal Financial Group’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-917
Closed -$34.5K – 2364
2024
Q1 		$34.5K Buy
917
+182
+25% +$7.53K ﹤0.01% 2370
2023
Q4 		$22.2K Sell
735
-58
-7% -$1.26K ﹤0.01% 2381
2023
Q3 		$17.4K Hold
793
– – ﹤0.01% 2422
2023
Q2 		$30.8K Sell
793
-230
-22% -$20.3K ﹤0.01% 2390
2023
Q1 		$94.3K Sell
1,023
-31
-3% -$3.89K ﹤0.01% 2307
2022
Q4 		$151K Buy
+1,054
New +$263K ﹤0.01% 2240

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Principal Financial Group's ACET Position: Q2 2024 in Review

Principal Financial Group sold out of Adicet Bio (ACET) in Q2 2024, closing a stake of 917 shares — an estimated $34.5K sold.

Principal Financial Group first reported a position in ACET in Q4 2022 and held it in 6 quarters. The position peaked at $151K in Q4 2022. 86 funds tracked by Wall St. Rank hold ACET as of Q2 2024.

  • Principal Financial Group reported no remaining Adicet Bio position as of Q2 2024 after selling out during the quarter.
  • Principal Financial Group sold 917 Adicet Bio shares in Q2 2024, an estimated $34.5K.
  • Principal Financial Group first reported a position in Adicet Bio in Q4 2022 and held it in 6 quarters.
  • Principal Financial Group's Adicet Bio position peaked at $151K in Q4 2022.
  • 86 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2024.

Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.